Johannes, C. B., Beachler, D. C., Layton, J. B., Danysh, H. E., Ziemiecki, R. ., Arana, A. ., … Gilsenan, A. . (2022). Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01263-3
A. Arana
First name
A.
Last name
Arana
Danysh, H. E., Johannes, C. B., Beachler, D. C., Layton, J. B., Ziemiecki, R. ., Arana, A. ., … Gilsenan, A. . (2022). Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01262-4
Arana, A. ., Varas, C. ., Gonzalez-Perez, A. ., Gutierrez, L. ., Bjerrum, L. ., & Rodriguez, L. A. G. (2006). Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause. http://doi.org/10.1097/01.gme.0000233494.28335.71
Arana, A. ., Johannes, C. B., McQuay, L. J., Varas-Lorenzo, C. ., Fife, D. ., & Rothman, K. J. (2015). Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide: A Population-Based Nested Case-Control Study. Drug Saf. http://doi.org/10.1007/s40264-015-0338-0
Varas-Lorenzo, C. ., Arana, A. ., Johannes, C. B., McQuay, L. J., Rothman, K. J., & Fife, D. . (2016). Improving the Identification of Out-of-Hospital Sudden Cardiac Deaths in a General Practice Research Database. Drugs Real World Outcomes. http://doi.org/10.1007/s40801-016-0086-1
Margulis, A. V., Fortuny, J. ., Kaye, J. A., Calingaert, B. ., Reynolds, M. ., Plana, E. ., … Arana, A. . (2018). Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. Epidemiology. http://doi.org/10.1097/ede.0000000000000856
Arana, A. ., Margulis, A. V., McQuay, L. J., Ziemiecki, R. ., Bartsch, J. L., Rothman, K. J., … Perez-Gutthann, S. . (2018). Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study. Pharmacotherapy. http://doi.org/10.1002/phar.2121
Kaye, J. A., Margulis, A. V., Fortuny, J. ., McQuay, L. J., Plana, E. ., Bartsch, J. L., … Arana, A. . (2017). Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias. Pharmacotherapy. http://doi.org/10.1002/phar.1932
Margulis, A. V., Fortuny, J. ., Kaye, J. A., Calingaert, B. ., Reynolds, M. ., Plana, E. ., … Arana, A. . (2018). Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom. Epidemiology. http://doi.org/10.1097/ede.0000000000000786
Margulis, A. V., Linder, M. ., Arana, A. ., Pottegard, A. ., Berglind, I. A., Bui, C. L., … Hallas, J. . (2018). Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. http://doi.org/10.1371/journal.pone.0204456